SalioGen was honored to participate in the recent 2024 Cystic Fibrosis Foundation Research Conference. The innovation in this field is exciting, and we're inspired by the dedication and passion of the individuals and organizations driving this progress. Learn more about the work we're doing in CF: https://bit.ly/3X2e1Bk
SalioGen Therapeutics
Biotechnology Research
Lexington, Massachusetts 3,723 followers
Accelerating the impact of genetic medicines for patients with Gene Coding™ technology
About us
SalioGen Therapeutics is a biotechnology company on a mission to accelerate the impact of genetic medicine for patients using its novel Gene Coding™ technology. Gene Coding is a non-viral method of integrating large or multiple whole genes into the genome at precise locations through transposition. This mechanism does not induce double-strand breaks or use guide RNA and has the potential to overcome the safety risks and limitations of other genetic medicine approaches. SalioGen's lead programs focus on one-time treatments for Stargardt disease and cystic fibrosis. The company is also developing its Gene Coding technology for additional indications, such as other inherited retinal diseases, and to engineer CAR-T cells for cancer and autoimmune conditions.
- Website
-
http://www.saliogen.com
External link for SalioGen Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Lexington, Massachusetts
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Gene therapy, Genome engineering, Cell therapy, Genetic disease, Inherited disease, and Cell engineering
Locations
-
Primary
Get directions
10 Maguire Rd
Building 1, Suite 200
Lexington, Massachusetts 02421, US
Employees at SalioGen Therapeutics
Updates
-
Gene Coding™ technology is a non-viral method of integrating large pieces of DNA, including large or multiple genes, into specific locations in the genome through transposition without relying on double-strand breaks or guide RNA. Learn more: https://bit.ly/3KpX6Bs
-
-
Tune in to this episode of #TheIssue with our CEO Jason Cole as he delves into our Gene Coding™ technology, recent progress in #Stargardt disease and #cysticfibrosis, and the importance of differentiated genetic medicine in addressing patients' unique and unmet needs.
🎧 In this episode of #TheIssue, Emily Walsh Martin, PhD, explores the cutting-edge transposase-based technology presented by SalioGen Therapeutics at #ASGCT2024 in which they achieved gene insertion without double-strand breaks. https://lnkd.in/gshYekQV Join us as Jason Cole, CEO at SalioGen Therapeutics, takes us on a captivating journey through the company's groundbreaking work, including their initial data in #Stargardt disease using LNP delivery to photoreceptors. Discover Jason's unconventional path from small molecules to genetic medicines and gain insights into the strategic value of using a target product profile to guide development decisions. Finally, we delve into the transformative potential of genetic medicine, bridging the gap from bench to bedside to payer-to-patient access. More information in the comments!
Gene Insertion Tech with Jason Cole, CEO of SalioGen—ASGCT's The Issue
https://www.youtube.com/
-
The buzz around non-viral gene integration technology at #ASGCT24 was strong, and we're proud to be at the forefront of the next generation of genetic medicine with our novel Gene Coding™ technology. Learn more: https://bit.ly/3KpX6Bs
-
-
Today we announced a strategic collaboration with Nanite to develop a non-viral, lung-targeting nanoparticle for our CF genetic medicine. This collaboration represents another important step forward in our R&D efforts to create the first permanent therapy for people with CF, regardless of the mutation. Learn more: https://bit.ly/3R7CEJk
-
-
This is a good one! Check out our CEO's interview on ByoBytes with Shakir Bux, where Jason Cole delves into his unconventional career path to SalioGen and its impact on fostering a corporate culture centered on patients, ambition, focus, and collaboration: https://bit.ly/3RjNPPh
S2, Ep 2. Jason Cole - CEO & Chair of the Board, SalioGen
https://www.youtube.com/
-
Rain or shine, Team Jumping Genes was unstoppable this weekend. Employees, partners, kids and pets came together, taking steps to find a cure for cystic fibrosis at the #GreatStrides event in Boston. We are grateful for the opportunity to support the Cystic Fibrosis Foundation and work towards a future when CF = Cure Found.
-
-
It’s #CFAwarenessMonth, and the theme is resilience. This is a time to celebrate the strength and achievements of people with cystic fibrosis (CF) and acknowledge the perseverance they have shown in the face of adversity. At SalioGen, we’re committed to empowering people in the CF community to live their best lives. Learn more about the one-time, permanent cure we’re developing for everyone with CF—regardless of mutation: https://bit.ly/4deafe4
-
-
At SalioGen, we’re committed to developing next-generation genetic medicines for inherited retinal diseases (IRDs) and are proud to support Inherited Retinal Disease Genetic Testing Month in May. Genetic testing for IRDs can provide valuable information to help plan for the future. It can confirm a diagnosis, inform a treatment regimen, and determine eligibility for clinical trials testing potential treatments. Learn more at Prevent Blindness: https://bit.ly/44cPgUO
-
-
That’s a wrap on a jam-packed week of game-changing science and big ideas at #ARVO2024 and #ASGCT24. We are invigorated by the innovation happening in genetic medicine and inspired by the people advancing it to improve patients’ lives. #ICYMI, here’s a link to our data presentations this week: https://bit.ly/3QyiIPo
-